bioMérieux Shares Bounce Near 50-Day Moving Average After Over 40% Yearly Decline
bioMérieux shares are making a comeback in today's session, in a rising Parisian market. The Lyon-based stock, weakened by a decline of more than 40% over the year, attempts to regain its footing on its short-term moving averages after a challenging quarter.
A Rebound Bringing the Stock Back to its 50-Day Moving Average
bioMérieux shares are up 1.87% at €70.85, up from €69.55 the previous day. The stock has moved above its 20-day moving average (€68.96) and is exactly at its 50-day moving average (€70.81), a level that has become resistance after several sessions of weakness. The RSI at 49 indicates a current balance between buyers and sellers, without a clear directional signal. The medium-term outlook remains weakened: the price is more than 25% below its 200-day moving average at €94.77, a gap reflecting the significant drop since the start of the year. Over three months, the decline reaches 24.35%, and the yearly drop is over 40%. Today's rebound allows the Lyon-based group to approach its identified resistance at €74.35, while support at €66.60 frames the lower part of the recent channel.
Women's Health Diagnostics and Food Safety: Two Recent Launches to Expand the Range
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
In terms of business activity, the group has multiplied product initiatives in recent weeks. At the end of June, bioMérieux submitted a 510(k) authorization request to the FDA for its Biofire Spotfire Vaginitis Panel, a molecular diagnostic test capable of identifying the causes of vaginitis in twenty minutes. This move marks the Lyon-based diagnostician's entry into women's and sexual health. A few days earlier, in mid-June, the company launched GENE-UP TYPER SLM, a PCR test targeting Salmonella in the agri-food sector, complementing the range launched at the beginning of 2025. These announcements are part of the strategy to broaden the molecular portfolio. The stock's behavior around its 50-day moving average will be the first indicator to follow to assess the strength of the ongoing rebound.
SectorSanté · Vaccins et laboratoires de recherche›Équipements Médicaux
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2025
Guidance from the release
Dans un contexte de faible activité épidémiologique, nous continuons à faire croître notre base installée, en particulier pour BIOFIRE® et SPOTFIRE®, et à améliorer la rentabilité dans le cadre du plan GO•28.
Ventes consolidées de 2 992 millions d'euros sur 9 mois (+4,2 % publié, +7,3 % organique). Forte croissance des panels non-respiratoires et de SPOTFIRE (croissance organique 114 %), ralentissement en Chine et moindre épidémiologie respiratoire. Révision de la guidance organique 2025 à +5,5 % / +6,5 %; ROCC attendu +12 % / +18 %. Effet de change négatif -85 millions d'euros sur les ventes 9 mois et ~-30 millions d'euros attendu sur le CEBIT annuel.
Risks mentioned
faible activité épidémiologique impactant les ventes de panels respiratoires
recul significatif des ventes en Chine
risque de change défavorable (impact -85 millions d'euros sur 9 mois, ~-30 millions d'euros sur CEBIT attendu)
risques liés aux économies en hyperinflation (Argentine, Turquie)
Opportunities identified
forte dynamique de SPOTFIRE (base installée >5 500, +160 % sur 12 mois)
croissance des panels non-respiratoires BIOFIRE
développements de nouveaux produits (GENE-UP® PRO HRM) et lancements soutenant les applications industrielles
croissance robuste des Applications Industrielles, notamment Contrôle Qualité Pharmaceutique (+15 %)
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
